Clinical trials: Atopy
Atopic Dermatitis
Oral DS107 in Moderate to Severe Atopic Dermatitis
This study will compare the safety and efficacy of Oral DS107 (2 g) to placebo in patients with moderate to severe atopic dermatitis. Oral DS107 (2 g) will be orally administered for 8 weeks, and will be compared against placebo.
- Trial name
- NCT02211417
- Testing
- Oral DS107
- Where
- 14 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Dignity Sciences Ltd.
Atopic Dermatitis
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.
- Trial name
- PEER (NCT00568997)
- Testing
- Pimecrolimus
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Bausch Health Americas, Inc.
Atopic Dermatitis
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to <18 years of age with moderate to severe AD.
- Trial name
- JADE TEEN (NCT03796676)
- Testing
- PF-04965842, PF04965842
- Where
- 136 sites in United States, Australia and 12 more
- Volunteers
- 287 people
- Sponsor
- Pfizer
Atopic Dermatitis
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new tablet (LEO 152020) to see if it improves AD and what the side effects are…
- Trial name
- NCT05117060
- Testing
- LEO 152020 tablet
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 216 people
- Sponsor
- JW Pharmaceutical
Atopic Dermatitis
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
- Trial name
- NCT05717920
- Testing
- ADX-629 (Open-label)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Asthma
Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma
The purpose of this study is to evaluate the effect of IMA-026, an antibody to IL-13, on airway hyperresponsiveness and airway inflammation in mild asthmatics.
- Trial name
- NCT00725582
- Testing
- IMA-026
- Volunteers
- 24 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Atopic Dermatitis
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the…
- Trial name
- NCT03725722
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 251 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD…
- Trial name
- ADface (NCT07873801)
- Testing
- Lebrikizumab
- Volunteers
- 230 people
- Sponsor
- Almirall, S.A.
Dermatitis Atopic
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab…
- Trial name
- NCT06686628
- Testing
- Amlitelimab, Midazolam, Caffeine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Sanofi
Atopic Dermatitis
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical…
- Trial name
- ADhere (NCT04250337)
- Testing
- Lebrikizumab, Topical Corticosteroid
- Where
- 63 sites in United States, Canada and 2 more
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis
This clinical trial will study the effects of PUFA supplementation during pregnancy and lactation period on fatty acid composition in human milk and plasma of the mothers and the clinical outcome of atopic dermatitis in infants…
- Trial name
- NCT01936194
- Testing
- DHA+EPA, High Olive Oil, DHA
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mead Johnson Nutrition
Atopic Dermatitis
Topical Solution for the Treatment of Atopic Dermatitis
The study is designed as a proof of concept, multi-center, randomized, double-blind and vehicle-controlled study with intra-individual comparison of treatments.
- Trial name
- CYCLATOP (NCT02865356)
- Testing
- Cyclosporine 5% solution
- Where
- 9 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Spherium Biomed
Atopic Dermatitis
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
- Trial name
- NCT03568331
- Testing
- Tradipitant
- Where
- 70 sites in United States
- Volunteers
- 375 people
- Sponsor
- Vanda Pharmaceuticals
Atopic Dermatitis
A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients
Assess Hemay808 concentration of 1%/3%/7% for treatment of mild and moderate adult atopic dermatitis patients.
- Trial name
- NCT04352595
- Testing
- Hemay808
- Where
- 2 sites in China
- Volunteers
- 148 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Atopic Dermatitis
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
- Trial name
- RE-UNITE AD (NCT06988605)
- Where
- 108 sites in United States, Germany and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of 2 doses of S-777469 in patients with atopic dermatitis.
- Trial name
- NCT00703573
- Testing
- S-777469 400 mg, S-777469 800 mg
- Where
- 33 sites in United States
- Volunteers
- 209 people
- Sponsor
- Shionogi
Atopic Dermatitis (AD)
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).
- Trial name
- NCT05456529
- Testing
- Ruxolitinib Cream
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical…
- Trial name
- NCT03703102
- Testing
- KHK4083
- Where
- 58 sites in United States, Canada and 2 more
- Volunteers
- 274 people
- Sponsor
- Kyowa Kirin, Inc.
Atopic Dermatitis
Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis
The purpose of this study is to determine whether PR022 Topical Gels are safe and effective treatments for mild-to-moderate atopic dermatitis (AD).
- Trial name
- NCT03351777
- Testing
- PR022
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Realm Therapeutics, Inc.
Atopic Dermatitis (AD), Eczema
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
- Conditions
- Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis
- Trial name
- NCT06723405
- Testing
- EVO301
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 71 people
- Sponsor
- Evommune, Inc.